Recently heterozygous mutations in the active site of the enzyme isocitrate dehydrogenase 1 (IDH1) were discovered in glioblastomas \[[@B1]\]. In cohorts of glioma patients the *IDH1* mutation appeared to be a strong predictor of clinical outcome, overruling histological malignancy grade \[[@B2]\]. IDH1 is an enzyme of the tricarboxylic acid (TCA) cycle and is located in the cytosol, where it produces NADPH by transforming isocitrate into α-ketoglutarate. Because the mutant enzyme displays neomorphic activity through NADPH-dependent transformation of α-ketoglutarate into 2-hydroxyglutarate (2HG), the tumorigenic role of the increased levels of 2HG has become a target of speculation \[[@B3]\]. *IDH1* mutation alters the cellular metabolism and epigenetic phenotype influencing cellular proliferation. *IDH1* mutation infers increased levels of *D2HGDH* leading to the inhibition of DNA and histone demethylating enzymes, resulting in the glioma-CpG island phenotype \[[@B4]\]. Altered concentrations of pyruvate kinase M2 play also a role in histone modifications which are associated with the transcription of the proliferation-related cyclin D1 and c-MYC \[[@B5]\]. In addition, *IDH1* mutant cells show alterations in glutamine, fatty acid and citrate synthesis pathways, which all may have their influence on cellular proliferation \[[@B5]\].

The changes in *IDH1* function affect the glucose metabolism, which may explain the different biological behaviour of tumors with and without the *IDH1* mutation \[[@B6]\]. In order to detect these changes, we compared the expression levels of the genes participating in the TCA cycle and in the anaerobic glycolysis in 33 *IDH1* mutated samples (3 astrocytomas WHO grade II; 6 astrocytomas WHO grade III; 4 glioblastomas; 9 oligodendrogliomas WHO grade II; 11 oligodendrogliomas WHO grade III) and in 39 *IDH1* wild-type glioma samples (10 astrocytomas WHO grade III; 26 glioblastomas; 1 oligodendroglioma WHO grade II; 2 oligodendroglioma WHO grade III) and in four samples of normal brain (Table [1](#T1){ref-type="table"}). We found expressional differences of 16/24 genes (Figure [1](#F1){ref-type="fig"}). The *IDH1* mutated cells seem to compensate for the low production of α-ketoglutarate by overexpressing *D2HGDH* and *L2HGDH* in the cytoplasm. They also overexpress *GLUD1*, which converts glutamate to α-ketoglutarate inside the mitochondria. In addition, we found that *IDH1* mutated cells overexpress *HIF1AN. The HIF1AN* gene inhibits *HIF1α.* Since *HIF1α* acts as an oxygen sensor that promotes angiogenesis, the formation of dysfunctional tumor vasculature is counteracted in *IDH1* mutated cells. Furthermore, the *IDH1* mutated cells overexpress the *LDHB* gene while cells without *IDH1* mutation overexpress the *LDHA* gene. The present results illustrate that tumor cells without *IDH1* mutation switch their energy production from a low rate of glycolysis followed by the TCA cycle to a high rate of glycolysis followed by aerobic glycolysis (*LDHA* up-regulation; Figure [1](#F1){ref-type="fig"}). The resulting lactate acid production causes tissue acidosis known as the Warburg effect. In invasive cancers, the pH of the extracellular space increases the infiltrative potential of the tumor cells \[[@B7]\]. In addition, normalization of the extracellular pH by alterations of the enzymatic actions of *LDHA* and *LDHB* influences the progression of cancer cells \[[@B8],[@B9]\]. It may well be that glial tumor cells with *IDH1* mutation tend to correct their energy production through the TCA cycle by overexpressing *LDHB* (Figure [1](#F1){ref-type="fig"}). By doing so, they normalize the tissue pH which offers yet another explanation for the less aggressive biological behavior of the *IDH1* mutated gliomas.

###### 

Percentages of glioma types and grades

  **WHO grades**   **IDH1 mutation**   **IDH1 wild type**
  ---------------- ------------------- --------------------
  A II             4%                  0%
  A III            8%                  14%
  GBM              6%                  36%
  O II             13%                 1%
  O III            15%                 3%

Legends: *A II* low-grade astrocytoma (WHO grade 2), *A III* anaplastic astrocytoma (WHO grade 3), *GBM* glioblastoma (WHO grade 4), *O II* low-grade oligodendroglioma (WHO grade 2), *O III* anaplastic oligodendroglioma (WHO grade 3).

![**Overview of alterations in glucose metabolism in the*IDH1*mutated and*IDH1*wild-type gliomas relative to glucose metabolism in normal brain.** The enzymes included in the analysis are shown in black. The bar diagrams show the averaged expressional levels of genes that were significantly differently expressed in the *IDH1* mutated gliomas (n = 33, blue bars on the left); *IDH1* wild-type (n = 39, red bars in the middle); and normal brain (n = 4, green bars on the right). Glycolysis leads to the production of pyruvate. In normal brain, pyruvate is converted to acetyl-CoA, which enters the TCA cycle in the mitochondria. But in the IDH1 wild-type tumors, pyruvate is metabolized to lactate ("the Warburg effect" in which the aerobic glycolysis serves as a quick energy source that results in tissue acidosis). To ensure the origin and quality of the tissues, all tissues were assessed by a qualified pathologist before isolation. IDH1 status was checked using IHC and the standard PCR test. Total RNA was isolated with the RNA-Bee (Campro, Veenendaal, The Netherlands). cDNA was prepared using the RevertAid H Minus First Strand cDNA synthesis kit (Fermentas, St Leon-Rot, Germany). The resulting cDNA preparations were analysed by real-time PCR with SYPR green master mix solution (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). PCRs were performed in a 25 μL reaction volume in an Applied BioSystems 7900HT Fast Real-Time PCR system. Negative controls included minus RT and H~2~O-only samples, which were negative in all cases. Expression of *B2M*, *HPRT1* and *PBGD* was used as a reference to control sample loading and RNA quality. Differences in mRNA concentrations were determined using the *t-*test, with P \< 0.01 being considered statistically significant. All statistical tests were two-sided.](2051-5960-2-6-1){#F1}

We conclude that gliomas with *IDH1* mutation normalize their glucose metabolism, which appears to result in a slower tumor progression. Depending on the *IDH1* status of the tumor, specific interference with the glucose metabolism and aerobic glycolysis should therefore be considered for future therapeutic strategies.
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